Changes, delays, and cancellation of cancer treatment and ancillary care reported.
Of more than 100 studies used to support drug approvals, none reported information on the gender of participants.
Patients with certain cancers have an increased risk of cancer-specific mortality that persists for 30 to 35 years after diagnosis.
The use of proton beam therapy (PBT) increased between 2004 and 2018, particularly for cancers in which the effectiveness of PBT is still under investigation.
Orteronel is likely not effective when compared with recently approved agents, according to researchers.